<DOC>
	<DOCNO>NCT01407874</DOCNO>
	<brief_summary>To evaluate overall safety tolerability ulodesine combine allopurinol subject moderate renal insufficiency .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Dose-Response Study Safety Uric Acid Effects Oral Ulodesine Added Allopurinol Subjects With Gout Concomitant Moderate Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>1 . Age ≥ 18 &lt; 70 year 2 . Have read sign Informed Consent Form 3 . Documented diagnosis gout 4 . Documented moderate renal insufficiency 5 . Calculated creatinine clearance ≥ 30 &lt; 60 mL/min 6 . Willing able take allopurinol 200 mg every day duration Treatment 7 . Female participant must sexually abstinent 4 week prior Day 1 continue abstinence 4 week completion study drug , surgically sterile , postmenopausal , use oral contraceptive three month prior study drug dose 4 week completion study drug , intrauterine device 8 week prior study drug dose 4 week completion study drug , double barrier contraception method 4 week prior study drug dose 4 week completion study drug administration 8 . Male participant must sexually abstinent 4 week prior Day 1 continue abstinence 90 day completion study drug , &gt; 1 year postvasectomy , agree use condom spermicide start study drug dose 90 day completion study drug . 9 . Willing able provide authorization use disclosure personal health information accordance Health Insurance Portability Accountability Act ( HIPAA ) 1 . Unable tolerate allopurinol 200 mg every day 2 . Prior randomization clinical study BCX4208 3 . Unstable cardiac disease : unstable angina , symptomatic arrhythmia , sign symptom compatible NYHA Class III Class IV functional status congestive heart failure angina , history long QT syndrome , QTc interval &lt; 350 msec &gt; 475 msec 4 . Poorly control hypertension 5 . History severe renal insufficiency 6 . Alanine aminotransferase aspartate aminotransferase value &gt; 2.0 x upper limit normal 7 . CD4+ cell count flow cytometry &lt; 500 cells/mm3 8 . Hemoglobin &lt; 10 g/dL &gt; 18 g/dL ( male ) &lt; 10 g/dL &gt; 17 g/dL ( female ) 9 . White blood cell count &lt; 3.7 x 109/L &gt; 11 x 109/L 10 . Female subject pregnant , breastfeeding , plan pregnancy within next 4 month 11 . Positive serology hepatitis B surface antigen hepatitis C antibody HIV type 1 12 . Immunocompromised due illness organ transplant 13 . Use systemic immunosuppressive medication diseasemodifying antirheumatic drug 14 . Use azathioprine 6mercatopurine within 14 day first dose allopurinol 15 . Use hydrochlorothiazide dos &gt; 50 mg per day 16 . Planned use herbal dietary supplement 17 . Recipient live attenuate vaccine within 6 week Screening 18 . Planned use uric acidlowering drug allopurinol 19 . Use systemic corticosteroid within 4 week prior Day 1 20 . Use investigational drug within 30 day prior sign ICF 21 . History clinically significant relevant drug allergy 22 . History chronic recurrent infection 23 . History type cancer successfully treat full remission 12 month prior Screening 24 . History alcohol drug abuse within year prior sign ICF , current evidence substance dependence abuse 25 . Use prohibit medication within timeframes specify protocol 26 . Other medical condition , opinion Principal Investigator , would jeopardize safety study subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Gout</keyword>
	<keyword>Hyperuricemia</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Renal Insufficiency</keyword>
</DOC>